Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313476 | 0.90 | KMT2A (0.34) | S1PR1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL12337359 | 0.82 | MEN1 (0.33) | S1PR1MEN1KMT2APOLBATM | |
| SCHEMBL12313481 | 0.81 | DHFR (0.33) | S1PR1MEN1KMT2APOLBATM | |
| SCHEMBL10039488 | 0.70 | TP53 (0.35) | ALDH1A1MEN1KMT2ADHFRPPARG | |
| SCHEMBL20906691 | 0.69 | LTA4H (0.35) | — | |
| SCHEMBL20906356 | 0.68 | SCN2A (0.33) | ALDH1A1RECQLRARARARBRARG | |
| SCHEMBL17565177 | 0.67 | HTR1A (0.43) | S1PR1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL7112190 | 0.67 | ALDH1A1 (0.48) | ALDH1A1RECQLMEN1KMT2AATM | |
| SCHEMBL11057543 | 0.66 | SHBG (0.44) | MEN1KMT2AATMSCN8APPARG | |
| SCHEMBL4687492 | 0.65 | HTR1A (0.42) | S1PR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263794-B2 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | ELOVL3, LIPA, FFAR2 | S1PR1 1533/4885ALDH1A1 1587/4885RECQL 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.